



Listing and evaluation of the results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 29 January 2020

Adviser:

Prof. Dr. med. Kai Gutensohn

MVZ aescuLabor Hamburg GmbH - amedes

Haferweg 36

22769 Hamburg

Tel.: +49 40 334411 880

Mail: kai.gutensohn@amedes-group.com

217

Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sam- ple	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
CD34+ Events	11	/µl	52.0	23.6	SV	18.9	28.3	120.3%	9,56	-	
	12		93.0	59.6	SV	47.7	71.5	56.0%	6,2	-	
Leucocytes	11	/µl	7958	7851	SV	6281	9421				
	12		13444	13636	SV	10909	16363				
CD45+ events (single platform)	11	/µl	7558	7659	SV	6127	9191				
	12		13061	13408	SV	10726	16090				
Viable CD45+ Events	11	/µl	7321	7138	SV	5710	8566				
	12		12772	12394	SV	9915	14873				
Viable CD34+ Events	11	/µl	48.0	23.1	SV	18.5	27.7	107.8%	9,36	-	
	12		88.0	57.8	SV	46.2	69.4	52.2%	5,49	-	
Viable CD34+ Events per viable CD45+ Events	11	%	0.660	0.324	SV	0.259	0.389				
	12		0.690	0.467	SV	0.374	0.560				

Analyte	Sam- ple	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device	Sample reception date	Sample processing date
CD34+ Events	11		52.0	1.00	222	BN	BN04	01/23/20	01/23/20
	12		93.0	1.00					
Leucocytes	11		7958		222	BN	BN04	01/23/20	01/23/20
	12		13444						
CD45+ events (single platform)	11		7558		222	BN	BN04	01/23/20	01/23/20
	12		13061						
Viable CD45+ Events	11		7321		222	BN	BN04	01/23/20	01/23/20
	12		12772						
Viable CD34+ Events	11		48.0	1.00	222	BN	BN04	01/23/20	01/23/20
	12		88.0	1.00					
Viable CD34+ Events per viable CD45+ Events	11		0.660		222	BN	BN04	01/23/20	01/23/20
	12		0.690						

Individual summary of results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 29 January 2020



217

Haematology 11 - Stem/Progenitor Cells (CD 34)

CD34+ Events (/μl, N = 79)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	23.6	18.9 - 28.3	23.6	12.6	79	89.9	88.6
	12	59.6	47.7 - 71.5	59.6	9.04	79	91.1	


Rate of success: 88,6%



Leucocytes (/μl, N = 13)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	7851	6281 - 9421	7851	3.43	13		
	12	13636	10909 - 16363	13636	5.87	13		


Rate of success: 92,3%



CD45+ events (single platform) (/μl, N = 74)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	7659	6127 - 9191	7659	8.38	74		
	12	13408	10726 - 16090	13408	8.67	74		


Rate of success: 89,2%



Viable CD45+ Events (/μl, N = 87)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	7138	5710 - 8566	7138	11.9	87		
	12	12394	9915 - 14873	12394	12.0	87		



Rate of success: 85,1%



Viable CD34+ Events (/μl, N = 87)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	23.1	18.5 - 27.7	23.1	11.5	87	87.4	86.2
	12	57.8	46.2 - 69.4	57.8	9.52	87	90.8	

Rate of success: 86,2%



Viable CD34+ Events per viable CD45+ Events (% , N = 86)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	0.324	0.259 - 0.389	0.324	10.5	86		
	12	0.467	0.374 - 0.560	0.467	9.64	86		

Rate of success: 86%

